BUSINESS
Lixiana Waging Hand-to-Hand Combat with Xarelto in DOAC Market: Encise FY2018 Snapshot
Daiichi Sankyo’s direct oral anticoagulants (DOAC) Lixiana (edoxaban) enjoyed bullish growth in Japan in the year ended March 2019, aggressively closing in on the market leader Xarelto (rivaroxaban), according to Encise’s FY2018 snapshot report released on April 5. On an…
To read the full story
Related Article
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





